1
|
Fransson J, Gómez-Conde AI, Romero-Imbroda J, Fernández O, Leyva L, de Fonseca FR, Chun J, Louapre C, Van-Evercooren AB, Zujovic V, Estivill-Torrús G, García-Díaz B. Activation of Macrophages by Lysophosphatidic Acid through the Lysophosphatidic Acid Receptor 1 as a Novel Mechanism in Multiple Sclerosis Pathogenesis. Mol Neurobiol 2021; 58:470-482. [PMID: 32974731 DOI: 10.1007/s12035-020-02130-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Accepted: 09/14/2020] [Indexed: 02/07/2023]
Abstract
Multiple sclerosis (MS) is a neuroinflammatory disease whose pathogenesis remains unclear. Lysophosphatidic acid (LPA) is an endogenous phospholipid involved in multiple immune cell functions and dysregulated in MS. Its receptor LPA1 is expressed in macrophages and regulates their activation, which is of interest due to the role of macrophage activation in MS in both destruction and repair. In this study, we studied the genetic deletion and pharmaceutical inhibition of LPA1 in the mouse MS model, experimental autoimmune encephalomyelitis (EAE). LPA1 expression was analyzed in EAE mice and MS patient immune cells. The effect of LPA and LPA1 on macrophage activation was studied in human monocyte-derived macrophages. We show that lack of LPA1 activity induces milder clinical EAE course and that Lpar1 expression in peripheral blood mononuclear cells (PBMC) correlates with onset of relapses and severity in EAE. We see the same over-expression in PBMC from MS patients during relapse compared with progressive forms of the disease and in stimulated monocyte-derived macrophages. LPA induced a proinflammatory-like response in macrophages through LPA1, providing a plausible way in which LPA and LPA1 dysregulation can lead to the inflammation in MS. These data show a new mechanism of LPA signaling in the MS pathogenesis, prompting further research into its use as a therapeutic target biomarker.
Collapse
Affiliation(s)
- Jennifer Fransson
- Institut du Cerveau et de la Moelle Epinière-Groupe Hospitalier Pitié-Salpêtrière, INSERM, U1127, CNRS, UMR 7225, F-75013, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie Paris 06, UM-75, F-75005, Paris, France
| | - Ana Isabel Gómez-Conde
- Unidad de Gestión Clínica de Neurociencias, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - Jesús Romero-Imbroda
- Unidad de Gestión Clínica de Neurociencias, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - Oscar Fernández
- Unidad de Gestión Clínica de Neurociencias, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - Laura Leyva
- Unidad de Gestión Clínica de Neurociencias, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - Fernando Rodríguez de Fonseca
- Unidad de Gestión Clínica de Neurociencias, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - Jerold Chun
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Celine Louapre
- Institut du Cerveau et de la Moelle Epinière-Groupe Hospitalier Pitié-Salpêtrière, INSERM, U1127, CNRS, UMR 7225, F-75013, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie Paris 06, UM-75, F-75005, Paris, France
- Neurology Department Pitié Salpétrière University. Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Baron Van-Evercooren
- Institut du Cerveau et de la Moelle Epinière-Groupe Hospitalier Pitié-Salpêtrière, INSERM, U1127, CNRS, UMR 7225, F-75013, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie Paris 06, UM-75, F-75005, Paris, France
| | - Violetta Zujovic
- Institut du Cerveau et de la Moelle Epinière-Groupe Hospitalier Pitié-Salpêtrière, INSERM, U1127, CNRS, UMR 7225, F-75013, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie Paris 06, UM-75, F-75005, Paris, France
| | - Guillermo Estivill-Torrús
- Unidad de Gestión Clínica de Neurociencias, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Regional Universitario de Málaga, Málaga, Spain.
| | - Beatriz García-Díaz
- Institut du Cerveau et de la Moelle Epinière-Groupe Hospitalier Pitié-Salpêtrière, INSERM, U1127, CNRS, UMR 7225, F-75013, Paris, France.
- Sorbonne Universités, Université Pierre et Marie Curie Paris 06, UM-75, F-75005, Paris, France.
- Unidad de Gestión Clínica de Neurociencias, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Regional Universitario de Málaga, Málaga, Spain.
| |
Collapse
|